SERUM ALBUMIN BINDING DISORDERS, PROTEIN AND LIPID METABOLISM AND ITS MANAGEMENT IN PATIENTS WITH ARTERIAL HYPERTENSION, COMBINED WITH NON-ALCOHOLIC STEATOHEPATITIS
DOI:
https://doi.org/10.11603/1811-2471.2020.v.i1.10728Keywords:
arterial hypertension, non-alcoholic steatohepatitis, Serum albumin binding function, Antral, protein metabolism, lipid metabolismAbstract
The last years showed the increased interest towards studying of arterial hypertension, due to the high rate of its pathology, which leads to a long-term loss of work ability. Importance of this problem is related as well with a low effectiveness of treatment of such patients. The important role in processing of this impairment belongs to different comorbid conditions, in particular nonalcoholic steatohepatitis (NASH), however pathogenesis of such combination is not yet enough researched.
The aim of the study – to suggest clinical, pathogenetic evaluation of disorders of serum albumin binding (DSAB) at hypertension with diastolic heart failure in patients with combined nonalcoholic steatohepatitis and offer a medication correction of presented changes.
Material and Methods. 40 volunteers with hypertension of stage II-III were divided into 2 groups. Group 1 contained patients with hypertension without a liver impairment, group 2 had those with combined non-alcoholic steatohepatitis. All patients were examined with a standard clinical examination, additionally they were examined their serum albumin binding function, protein fractions and lipidogram.
Results and Discussion. In patients of group 1 it was found a lipidogram disorder (atherogenic dyslipidemia), during a concomitant NASH credible decrease DSAB, as well as impairment of protein and lipid metabolism. The patients of both groups were receiving a basic antihypertensive therapy. Group 2 additionally received medication Antral 200 mg 3 times a day during 2 months. After conducted treatment there were found a credible increase of DSAB and improvement of protein fractions and lipid metabolism.
Conclusion. Comorbidity of arterial hypertension with non-alcoholic steatohepatitis is accompanied by a credible increase of DSAB and more profound changes in the protein and lipid metabolisms. Additional prescription of antral for such patients results in a significant increase of DSAB and normalization of protein and lipid metabolism.
References
Andreychyn, S.M., & Skirak, Z.S. (2014). Vplyv hlutarhinu na zviazuvalnu funktsiiu syrovatkovoho albuminu ta inshi pokaznyky funktsionalnoho stanu pechinky pry hostromu toksychnomu hidrazynovomu hepatyti [Effect of glutargin on serum albumin binding function and other indicators of liver functional status in acute toxic hydrazine hepatitis]. Medychna ta klinichna khimiia – Medical and Clinical Chemistry, 16, 4, 66-69 [in Ukrainian].
Skirak, Z.S. (2010). Vplyv preparatu hlutarhin na biokhimichni pokaznyky pry hostromu alkoholnomu hepatyti v umovakh eksperymentu [Effect of glutargine on biochemical parameters in acute alcoholic hepatitis in experimental conditions]. Naukovyi visnyk Uzhhorodskoho universytetu. Ser.: Medytsyna – Scientific Bulletin of Uzhhorod University. Ser.: Medicine, 38, 92-94 [in Ukrainian].
Skirak, Z.S. (2014). Pokaznyky endohennoi intoksykatsii ta lipoperoksydatsii v dynamitsi hostroho toksychnoho tetrakhlormetanovoho hepatytu [Indicators of endogenous intoxication and lipoperoxidation in the dynamics of acute toxic tetrachloromethane hepatitis]. Infektsiini khvoroby – Infectious Diseases, 3, 89-92 [in Ukrainian].
Nakaz MOZ Ukrainy № 384 vid 24.05.2012 roku “Pro zatverdzhennia ta vprovadzhennia medykotekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry arterialnii hipertenzii” [Order of the Ministry of Health of Ukraine No. 384 of May 24, 2012 “On approval and implementation of medical-technological documents on standardization of medical care for arterial hypertension”]. [in Ukrainian].
Nakaz MOZ Ukrainy № 826 vid 06.11.2014 “Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnykh neinfektsiinykh hepatytakh” [Order of the Ministry of Health of Ukraine No. 826 of 06.11.2014 “On approval and introduction of medical-technological documents on standardization of medical care in chronic non-communicable hepatitis”]. [in Ukrainian].
Lashkul, Z.V. (2014). Osoblyvosti epidemiolohii arterialnoi hipertenzii ta yii uskladnen na rehionalnomu rivni z 1999 po 2013 roky [Features of epidemiology of arterial hypertension and its complications at the regional level from 1999 to 2013]. Suchasni medychni tekhnolohii – Modern Medical Technologies, 2, 134 [in Ukrainian].
Hrebenyk, M.V., & Kotsiuba, O.I. (2016). Osoblyvosti korektsii diastolichnoi dysfunktsii livoho shlunochka u khvorykh na hipertonichnu khvorobu z hiperurykemiieiu [Features of correction of diastolic left ventricular dysfunction in patients with hypertension with hyperuricemia]. Liky Ukrainy – Medicines of Ukraine, 3 (199), 72 [in Ukrainian].
Vydyborets, S.V. (2018). Albumin: spektr mozhlyvostei zastosuvannia [Albumin: a spectrum of possibilities of application]. Semeynaya medytsyna – Family Medicine, 2 (76), 109 [in Ukrainian].
Kiriyenko, V.T., & Potii, V.V. (2015). Efektyvnist Antraliu u khvorykh na khronichnyi hepatyt C [Efficiency of Antral in patients with chronic hepatitis C]. Visnyk naukovykh doslidzhen – Bulletin of Scientific Researches, 3, 28-30 [in Ukrainian].
Leung, A.A., Daskalopoulou, S.S., Dasgupta, K., McBrien, K., Butalia, S., Zarnke, K.B., ..., & Rabi, D.M. (2017). Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can. J. Cardiol., 33 (5), 557-576. DOI: https://doi.org/10.1016/j.cjca.2017.03.005
Lago, R.M., Singh, P.P., & Nesto, R.W. (2007). Diabetes and hypertension. Nat. Clin. Pract. Endocrinol. Metab., 3 (10), 667. DOI: https://doi.org/10.1038/ncpendmet0638
Cheger, S.I. (1975). Transportnaya funktsiya syvorotochnogo albumina [Transport function of serum albumin]. Izdatelstvo: Bukharest: Akademiya Rumynii [in Russian].
Zhulkevich, I.V., & Vainshtein, S.G. (1986). Algorithm for phenotyping hyperlipoproteinemias and its application to the" Elektronika BZ-21" microcalculator. Laboratornoe delo, 10, 623-625.
Zvyagintseva, T.D., & Chernobay, A.I. (2016). Primeneniye preparata Antral v lechenii nealkogolnogo steatogepatita: nastoyashcheye i budushcheye [Application of the drug Antral in the treatment of non-alcoholic steatohepatitis: present and future]. Chelovek i lekarstvo – Man and Medicine, 17 (78), 84 [in Russian].
Babak, O.Ya., Fadeyenko, G.D., & Kolesnikova, Ye.V. (2010). Opyt primeneniya preparata Antral v sostave kompleksnoy terapii nealkogolnoy zhirovoy bolezni pecheni [Experience with the use of the drug Antral as a part of complex therapy of non-alcoholic fatty liver disease]. Consilium Medicum Ukraina, 4, 5, 22 [in Russian].
Samohalska, O.Ye. (2009). Efektyvnist preparatu “Antral” pry nealkoholnii zhyrovii khvorobi pechinky [Efficiency of the drug “Antral” in non-alcoholic fatty liver disease]. Suchasna hastroenterolohiia – Modern Gastroenterology, 5 (49), 85 [in Ukrainian].
